Gilead Sciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held on April 30, 2026. The filing covers the election of directors, ratification of auditors, executive compensation advisory vote, equity plan approval, and the outcome of three stockholder proposals.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
- Quorum: 1,130,179,690 shares were represented out of 1,241,222,013 entitled to vote.
- Director Elections: All nine nominees were elected. Votes against ranged from approximately 15 million (Javier J. Rodriguez) to 50 million (Daniel P. O'Day).
- Auditor Ratification: Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive Compensation: The advisory vote on Named Executive Officer compensation was approved.
- Equity Plan: The amended and restated 2022 Equity Incentive Plan was approved.
- Stockholder Proposals Rejected:
- Proposal for an independent Board Chair policy (approx. 22.6% For).
- Proposal for a report on extended patent exclusivities and patient access (approx. 10.8% For).
- Proposal for a report on ESG and DEI executive compensation metrics (approx. 0.6% For).
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk disclosures beyond the standard context of the annual meeting.
Investor Verification Checklist
- Verify the specific vote percentages for directors receiving the highest "Against" votes (Daniel P. O'Day and Harish Manwani) to assess board sentiment.
- Review the amended 2022 Equity Incentive Plan (Exhibit 10.1) for changes to share limits or vesting terms.
- Confirm the fiscal year-end date for the newly ratified auditor (December 31, 2026).
- Monitor future filings for any follow-up actions regarding the rejected stockholder proposals on governance and ESG.